Compare iShares MSCI China ETF (MCHI) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Tempus AI — how do they compare? iShares MSCI China ETF trades at $52.47 (market cap $5.94B), while Tempus AI trades at $71.21 (market cap $12.58B). The key difference: Tempus AI is far larger — about 2.1× iShares MSCI China ETF's market cap, and Tempus AI is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and Tempus AI for 22 Days on average.
| MCHI | TEM | |
|---|---|---|
Market Cap | $5.94B | $12.58B |
Volume | 1,575,471 | 7,444,569 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $65.59 | $99.28 |
52-Week Low | $50.48 | $41.55 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | — | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.46, up 1.59% today, but faces strong bearish technical signals with 13 sell signals on moving averages. The ETF's valuation remains historically cheap compared to US indices, with Seeking Alpha noting the discount despite significant tech exposure. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions ahead of key US-China meetings.
Outlook remains cautious given bearish technicals and China's macroeconomic headwinds, though the valuation discount presents potential opportunity. Key risks include US-China trade tensions and weak domestic consumption. Institutional activity shows mixed signals with recent purchases by Empowered Funds offset by sales from Acima Private Wealth.
Tempus AI (TEM) trades at $72.15, up 2.65% today, with a bullish technical signal and strong analyst support. The stock shows recent earnings beats but remains unprofitable, with a net income margin of -17.77% for 2026. Positive developments include FDA clearance for an AI product and expanded data partnerships, fueling investor optimism in the healthtech sector.
Outlook is cautiously optimistic given growth potential in AI-driven diagnostics, but high valuation (P/S 8.61) and persistent losses pose risks. Upside hinges on revenue scaling and path to profitability, with a consensus price target of $72.60 suggesting limited near-term gains from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
